Plasma concentration-time profiles of metformin (A), cephalexin (B) and creatinine (C) and cumulative urinary excretions of metformin (D), cephalexin (E) and creatinine (F) in control (open circles) and hyperuricemic rats (closed circles). Concentrations of metformin, cephalexin and creatinine in plasma and urine were measured up to 4 h after intravenous administration of metformin (30 mg/kg) or cephalexin (10 mg/kg). Creatinine concentration represents endogenous creatinine. Data are presented as mean ± SEM (n = 3). *p < 0.05 vs. control rats.</p
Metformin is the primary drug for type 2 diabetes treatment and a promising candidate for other dise...
Endogenous biomarkers for transporter-mediated drug-drug interaction (DDI) predictions represent a p...
AbstractMetformin is used as a probe for OCT2 mediated transport when investigating possible DDIs wi...
The effects of hyperuricemia on the expression of kidney drug transporters and on the pharmacokineti...
The effects of hyperuricemia on the expression of kidney drug transporters and on the pharmacokineti...
Pharmacokinetic parameters of metformin, cephalexin and creatinine in control and hyperuricemic rats...
Changes in plasma AUC and concentration of each drug are shown in the blood column. Changes in kidne...
Metformin pharmacokinetics are highly dependent upon organic cationic transporters. There is evidenc...
INTRODUCTION: Metformin can accumulate and cause lactic acidosis in patients with renal insufficienc...
Plasma concentrations of BUN and creatinine and inulin clearance in control and hyperuricemic rats.<...
The pharmacokinetics of some hepatically cleared drugs have been reported to fluctuate in patients w...
Metformin, a biguanide, is widely used as an oral hypoglycemic agent for the treatment of type 2 dia...
Abstract: Current treatment strategies for chronic kidney disease (CKD) mainly focus on controlling ...
Blood serum and urine encompass a wide array of chemical molecules and enzymes that reflect the phys...
Metformin, the most widely prescribed anti-diabetic drug, requires transporters to enter tissues inv...
Metformin is the primary drug for type 2 diabetes treatment and a promising candidate for other dise...
Endogenous biomarkers for transporter-mediated drug-drug interaction (DDI) predictions represent a p...
AbstractMetformin is used as a probe for OCT2 mediated transport when investigating possible DDIs wi...
The effects of hyperuricemia on the expression of kidney drug transporters and on the pharmacokineti...
The effects of hyperuricemia on the expression of kidney drug transporters and on the pharmacokineti...
Pharmacokinetic parameters of metformin, cephalexin and creatinine in control and hyperuricemic rats...
Changes in plasma AUC and concentration of each drug are shown in the blood column. Changes in kidne...
Metformin pharmacokinetics are highly dependent upon organic cationic transporters. There is evidenc...
INTRODUCTION: Metformin can accumulate and cause lactic acidosis in patients with renal insufficienc...
Plasma concentrations of BUN and creatinine and inulin clearance in control and hyperuricemic rats.<...
The pharmacokinetics of some hepatically cleared drugs have been reported to fluctuate in patients w...
Metformin, a biguanide, is widely used as an oral hypoglycemic agent for the treatment of type 2 dia...
Abstract: Current treatment strategies for chronic kidney disease (CKD) mainly focus on controlling ...
Blood serum and urine encompass a wide array of chemical molecules and enzymes that reflect the phys...
Metformin, the most widely prescribed anti-diabetic drug, requires transporters to enter tissues inv...
Metformin is the primary drug for type 2 diabetes treatment and a promising candidate for other dise...
Endogenous biomarkers for transporter-mediated drug-drug interaction (DDI) predictions represent a p...
AbstractMetformin is used as a probe for OCT2 mediated transport when investigating possible DDIs wi...